Sector News

Mallinckrodt inks $1.2B Sucampo buy, ending rough 2017 on a high note

December 29, 2017
Life sciences

Mallinckrodt, which has landed in hot water multiple times this year, is diversifying beyond its controversial lead seller.

The company Tuesday agreed to shell out $18 per share for Sucampo and its debt, bringing the deal’s total value to about $1.2 billion. The takeover pact boosted shares of Mallinckrodt, which as of Friday were down 53% for the year, Bloomberg notes.

With Mallinckrodt’s new buy will come constipation med Amitiza, a drug shared with Takeda that Wall Street expects to generate $261 million in 2018 sales. The product bears indications in both chronic idiopathic constipation and opioid-induced constipation, as well as irritable bowel syndrome with constipation (IBS-C). And Sucampo is gunning for another: The FDA has already accepted the company’s application for a pediatric functional constipation indication, and it’s due to hand down a verdict by the end of January, Jefferies analyst Anthony Petrone wrote in a note to clients.

The acquisition brings Mallinckrodt access to a pair of Sucampo pipeline candidates, too, in rare diseases Niemann-Pick Type C and Familial Adenomatous Polyposis. Petrone, for one, puts peak sales of the prospects at a combined $450 million.

Mallinckrodt CEO Mark Trudeau touted the deal as “the latest milestone towards our vision of becoming an innovation-driven specialty pharmaceutical growth company.” The agreement follows the company’s move to leave industry trade group PhRMA—just 15 months after joining—ahead of new rules requiring member drugmakers to spend significant bucks on R&D.

Its been a rough year for the U.K.-based drugmaker, which in October was hit with a payer lawsuit accusing the company of blocking competition to lead med H.P. Acthar Gel and, along with previous owner Questcor, raising prices on it by 85,000% since 2001. Earlier in the year, it agreed to fork over $100 million to the FTC to wrap up a probe it inherited with its 2014 Questcor buy. And it also in April paid $35 million to settle an oxycodone diversion case with the Justice Department.

The way Petrone sees it, though, the company is ending 2017 on a high note. Based his current 2018 targets for Mallinckrodt, the transaction will pad revenue by 8% and earnings by 10%, he wrote.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.